IntegriChain Appoints Tim Murdoch as Chief Commercial Officer to Drive Continued Growth and Customer Value

IntegriChain, the leading provider of revenue optimization technology and insights for the pharmaceutical industry, announced the appointment of Tim Murdoch as Chief Commercial Officer. Murdoch – a seasoned enterprise technology sales and marketing executive with more than 20 years of experience at SaaS leaders such as Adobe, Salesforce, and SAP – brings a wealth of expertise in driving customer growth and adoption in companies that are transforming healthcare. Prior to joining IntegriChain, Murdoch was responsible for launching and driving the Adobe Experience Cloud for Healthcare, creating the fastest growing vertical market at Adobe.

Read More: River Logic Announces Partnership with Finstock for its Value Chain Optimization Solution

“IntegriChain has established itself as a market leader in commercialization and net revenue optimization for Pharma, experiencing significant customer growth and market expansion,” said Josh Halpern, Co-Founder and CEO of IntegriChain. “As we accelerate our investment in our ICyte Platform and grow its adoption in larger and more complex Pharm organizations, we are thrilled to welcome a commercial leader with Tim’s enterprise technology experience. The Board and I are confident in Tim’s ability to build a world-class commercial organization, cultivate strong C-level relationships within the Pharma industry, and drive continued customer growth and value realization.”

Read More: SalesTechStar Interview with Matt Curl, COO at Apollo.io

“This is a pivotal moment in IntegriChain’s journey and ICyte’s adoption, and I am excited to join the commercial leadership team and contribute to the company’s ongoing success,” said Murdoch. “IntegriChain is uniquely positioned to help Pharma set and execute more profitable strategies in this challenging pricing, access, and regulatory environment. I look forward to playing an integral role in advancing IntegriChain’s mission and supporting the commercialization of our customers’ life-changing innovative science.”